Gustavo Viani Examines Five Clinical Trials and Their Implications for Individualized Cancer Treatment at ESMO 2026
@gusviani
oncodaily.com/science/gustav…
GORTEC IDEAL at #ESMO2026:
Induction EGFR-ADC becotatug vedotin ± pucotenlimab before CRT in locally advanced HNSCC:
No grade 4 AEs in the first 20 patients.
Grade 3 AEs in 8/20.
Preliminary ORR: 71% (15 evaluable).
Early phase II data; efficacy remains immature.
@myESMO
oncodaily.com/oncolibrary/ra…
At #ESMO2026, a phase II trial of neoadjuvant nivolumab + docetaxel/cisplatin in high-grade salivary gland cancer reported:
MPR: 60.9%
pCR: 32.6%
2-year DFS: 76%
Promising results in 46 operated patients; randomized validation is needed.
@myESMO
oncodaily.com/oncolibrary/ra…
Five Radiation Oncology Studies From ESMO 2026 - Felipe Couñago
@fcounago
oncodaily.com/science/felipe…
UNION phase III at #ESMO2026:
Short-course RT + camrelizumab + CAPOX improved 3-year EFS in locally advanced rectal cancer.
91.3% vs 77.4% (HR 0.33; P=0.0029).
Grade ≥3 toxicity: 51.3% vs 48.2%.
Results presented by Zhen Yu Lin.
@myESMO
oncodaily.com/oncolibrary/ra…
DASL-HiCaP at #ESMO2026:
Adding darolutamide to ADT + RT improved 4-year metastasis-free survival in very high-risk prostate cancer.
MFS: 95% vs 88% (HR 0.42; P=0.0001).
PSA-PFS: 91% vs 83%.
OS benefit not yet established.
oncodaily.com/oncolibrary/ra…
@myESMO
Steven Lin Explores Precision Radiotherapy for Organ Preservation and Cancer Control - Toufic Kachaamy
@KachaamyMD
oncodaily.com/science/toufic…
NRG-GY020 at #ESMO2026:
Adding pembrolizumab to adjuvant RT did not improve 3-year RFS in early-stage high-intermediate-risk dMMR endometrial cancer.
RFS: 70% vs 73% (P=0.68).
3-year OS: 96% in both arms.
Grade 3–4 toxicity: 43% vs 15%.
@myESMO
oncodaily.com/oncolibrary/ra…
iNATURE at #ESMO2026:
Personalized neoantigen vaccine + precision RT improved median PFS to 10.3 vs 3.1 months with placebo + RT (HR 0.29) in 35 patients with advanced solid tumors.
No grade ≥3 vaccine-related AEs.
Promising phase II findings.
@myESMO
oncodaily.com/opinion/inatur…
GITG MASTERPLAN at #ESMO2026:
Adding SBRT to chemotherapy in pancreatic cancer reduced 12-month locoregional recurrence (20.2% vs 52.0%).
Median PFS: 11.9 vs 6.3 months.
Median OS: 22 vs 14 months.
Promising randomized results presented by Andrew Oar.
@myESMO
oncodaily.com/oncolibrary/ra…
ARION at #ESMO2026:
Adding durvalumab to definitive chemoradiotherapy did not improve PFS in locally advanced esophageal cancer.
12-month cPFS: 48.6% vs 48.9% (HR 0.91).
No significant OS benefit or new safety signals.
@myESMO
oncodaily.com/tag/esophageal…
TOP-1 at #ESMO2026:
Omitting both RT and endocrine therapy after breast-conserving surgery in 792 women ≥70 with low-risk ER+ breast cancer resulted in 14.8% local recurrence at 5 years.
Breast cancer-specific survival remained excellent.
oncodaily.com/oncolibrary/ra…
@myESMO
PR21 at #ESMO2026:
Lu-177 PSMA-617 showed better patient-reported QoL than docetaxel in mCRPC.
At week 30, FACT-P change was +4.7 vs −8.3 (P<0.001).
Side-effect bother: 15.4% vs 40.7%.
No significant rPFS difference.
oncodaily.com/oncolibrary/ra…
@myESMO
Freddy Escorcia to Share Research Insights on the Evolution of Radiopharmaceutical Therapy - Heath Skinner
@HSkinnerMDPhD
oncodaily.com/science/heath-…
Key Insights from ESMO 2026 - Jeff Ryckman
@jryckman3
oncodaily.com/science/jeff-r…
KEYNOTE-975 at #ESMO2026:
Adding pembrolizumab to definitive chemoradiotherapy failed to improve EFS in esophageal/GEJ cancer with PD-L1 CPS ≥10.
Median EFS: 15.2 vs 14.7 months (HR 0.97).
Phase 3 results presented by Manish Shah.
@myESMO
oncodaily.com/oncolibrary/ra…
SANO 5-year results at #ESMO2026:
Overall survival was 50% with active surveillance vs 54% with surgery after complete response to neoadjuvant CRT.
Distant metastases were higher (46% vs 29%), while 43% avoided non-beneficial esophagectomy.
oncodaily.com/oncolibrary/ra…
@myESMO
What’s new in lung cancer radiotherapy in 2026?
Four publications examine proton therapy in stage III NSCLC, pneumonitis risk after durvalumab, updated ESTRO–EORTC recommendations for SCLC, and real-world treatment gaps.
Read our OncoDaily RT roundup.
@ESTRO_RT
oncodaily.com/oncolibrary/ra…
🎯 What’s new in breast cancer radiotherapy in 2026?
Six publications cover preoperative RT, nodal irradiation de-escalation, cardiac toxicity, targeted therapy combinations, breast conservation in BRCA carriers, and knowledge-based VMAT.
Read our OncoDaily RT roundup.
oncodaily.com/oncolibrary/ra…
@ESTRO_RT
